Novo Nordisk - Oxford Fellowship Programme
The Novo Nordisk – Oxford Fellowship Programme aims to support the development of a new generation of exceptional researchers in the field of diabetes and other cardiometabolic diseases, who will become future leaders in the field.
Contact us
-
Nuala Simpson
Research Facilitator and Novo Nordisk–Oxford Fellowship Programme Operations Manager
-
Serena Briant
Senior Research Facilitator and Novo Nordisk Programme Manager
Supported by
Our aim
The Novo Nordisk – Oxford Fellowship Programme is focused on research in diabetes, cardiometabolism, liver and renal disease. It aims to support the development of a new generation of exceptional early career researchers, who will become future leaders in the field, while further developing scientific excellence and ultimately improving the lives of patients. We offer prestigious 3-year postdoctoral research fellowship positions in research projects that span the translational spectrum, from basic biological research through to clinical application.
What we offer
We offer fellows a cutting edge research project based at the University of Oxford, which is supervised by world-leading researchers in the field of diabetes and other cardiometabolic diseases. In addition, each fellow is given a mentor or supervisor at Novo Nordisk. There is also the opportunity to spend time in the laboratories of Novo Nordisk (both in Oxford and Denmark). This distribution of time will depend on the fellow's specific project. Fellows will therefore get an insight into research in both academia and industry.
Latest publications
-
Characterizing X-Ray and Solution State Conformations for a Model Qubit System: {Cr7Ni} Ring Rotaxanes on a Mixed Metal Triangle
Journal article
Loci L. et al, (2024), Inorganic Chemistry
-
Nicotinic signaling stimulates glucagon secretion in mouse and human pancreatic α-cells.
Journal article
Hamilton A. et al, (2024), Diabetes
-
Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes.
Conference paper
Hill TG. et al, (2024), Nat Metab
-
Sympathetic neuropeptide Y protects from obesity by sustaining thermogenic fat.
Journal article
Zhu Y. et al, (2024), Nature